Acarix AB (publ) publishes Year-End Report 2020
A strong ending of an eventful year


The fourth quarter contributed strongly to our overall performance in 2020, with the market approval
for CADScor® from the US Food and Drug Administration (FDA) as the outstanding achievement.
Extract from CEO Per Persson’s message to the End Year Report.

PM_Acarix_Year-End_2020 eng

PM_Acarix_Bokslutskommuniké_2020 sv



About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.